<DOC>
	<DOCNO>NCT02828046</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , PK/PD M281 single multiple dose healthy volunteer .</brief_summary>
	<brief_title>An Ascending Dose Study Evaluate M281 Safety , Tolerability , Pharmacokinetics ( PK ) Pharmacodynamics ( PD )</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male female subject 18 55 year , inclusive . 2 . Good health 3 . Body weight 50 110 kg inclusive 1 . History drug allergy , hypersensitivity , intolerance drug product opinion Investigator would place subject particular risk compromise safety subject study . 2 . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , oncologic , psychiatric disease , condition , opinion Investigator would jeopardize safety subject validity study result . 3 . History current diagnosis substance dependence ( except nicotine caffeine ) alcohol abuse past 2 year , accord criterion DSMIVTR . 4 . Smokes smoke 5 cigarette per day last 90 day unable stop smoking inpatient observation period clinic . 5 . Unwillingness abstain alcohol least 24 hour prior dose study medication time discharge study unit least 24 hour prior ambulatory visit . 6 . Plans participate another clinical trial enrol study and/or receive investigational drug and/or device within 60 day prior admission . 7 . Donation significant loss whole blood ( 480 mL ) within 30 day plasma within 14 day prior admission . 8 . History splenectomy , asthma ( exception childhood asthma resolve ) , COPD , recurrent current GI respiratory infection . 9 . On fluid restriction . 10 . Systemic steroid within 3 month prior start study drug administration , prescription medication ( ) within 14 day dose administration nonprescribed systemic topical medication ( include herbal product ) within 7 day prior dose administration . 11 . Vaccination within 1 month dosing , plan receive vaccination study . 12 . Any illness within 5 day , clinically significant airway infection within 30 day , prior first study drug dose . 13 . Positive urine drug screen ( UDS ) screening . 14 . Positivity human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>